Premium
Antibody against epstein‐barr virus dna polymerase activity in sera of patients with nasopharyngeal carcinoma
Author(s) -
Liu MeiYing,
Chou WenHsiang,
Chen JenYang,
Yang CzauSiung,
Nutter Louise,
Hsu MowMing
Publication year - 1989
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890280209
Subject(s) - nasopharyngeal carcinoma , antibody , virology , virus , dna polymerase , herpesviridae , polymerase , epstein–barr virus , deoxyuridine , biology , immunology , medicine , enzyme , dna , microbiology and biotechnology , viral disease , biochemistry , genetics , radiation therapy
A salt‐dependent DNA polymerase activity was demonstrated in the culture of an EBV‐producing, lymphoblastoid cell line (NPC‐204 cells) treated with 5‐iodo‐2′‐deoxyuridine (IUdR). There was a high frequency of levels of antibody to this enzyme in sera of patients with nasopharyngeal carcinoma (NPC). In contrast, sera from healthy subjects had little or no neutralizing activity. The high antibody level appeared as early as stage 1 of the disease in many NPC patients. The levels of the antibody increased with the progression of the disease and declined in treated patients. The results strongly suggest that tests measuring serum antibody against EBV DNA polymerase activity can be used for early diagnosis and prognosis of NPC.